A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a condition called anti-LGI1 encephalitis, which is a type of autoimmune encephalitis. This means that the body’s immune system mistakenly attacks the brain, leading to symptoms like seizures, memory problems, changes in behavior, and sleep issues. The goal of the study is to better understand how this condition affects patients and what factors might influence their recovery. Although many patients respond well to treatment, some may experience ongoing problems like seizures or memory loss, so researchers want to learn more about the long-term outcomes.

To participate in this study, you need to be newly diagnosed with anti-LGI1 encephalitis and in the early stages of the condition. You must also be between 18 and 75 years old and able to give written consent to join the trial. Throughout the study, participants will undergo various tests and evaluations to help researchers gather important information. This study aims to improve our understanding of the condition and ultimately enhance care for patients with anti-LGI1 encephalitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.
• • 2. Newly diagnosed, and during the acute stage before study enrollment.
• • 3. Sign the informed consent form.
• Exclusion Criteria:
• • 1. with the diagnosis of epilepsy, stroke, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis.
• • 2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.
• • 3. Lost to follow-up.